Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.49 |
| ▸ | BTK | Q06187 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 11/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018112 | 0.83 | JAK3 (0.69) | JAK3BTKJAK2JAK1 | |
| SCHEMBL12085371 | 0.79 | SYK (0.51) | BTKSYK | |
| SCHEMBL4377726 | 0.73 | JAK3 (0.56) | JAK3BTKJAK2JAK1 | |
| SCHEMBL13859261 | 0.71 | EGFR (0.59) | JAK3BTKJAK2JAK1EGFR | |
| SCHEMBL14320055 | 0.70 | CDK2 (0.44) | JAK3JAK2SYKLCK | |
| SCHEMBL14311440 | 0.70 | LRRK2 (0.40) | JAK3JAK2SYKLCK | |
| SCHEMBL18656942 | 0.69 | SYK (0.44) | SYK | |
| SCHEMBL23195805 | 0.68 | MAPK8 (0.58) | JAK3BTKJAK2JAK1SYK | |
| SCHEMBL23196346 | 0.68 | JAK3 (0.51) | JAK3BTKJAK2JAK1 | |
| SCHEMBL14320053 | 0.67 | LRRK2 (0.44) | JAK3BTKJAK2JAK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | JAK3 6/4885BTK 2/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.